Although umbilical cord blood (UCB) transplantation has been practiced for nearly one decade, it has largely been applied to children and small adults due to the general misconception that the number of hematopoietic stem cells in each unit of UCB would not be adequate for a full adult transplant. In the last few years, there has been an increase in the number of adults transplanted using UCB.
1-2 With a recent report of the successful use of hematopoietic stem cells pooled from two different units of unrelated UCB that may not necessarily be HLA-matched, 3 it is expected that UCB transplantation will become a more widely applicable therapeutic option for adult patients.
Severe aplastic anemia (SAA) is a recognized complication of viral hepatitis. Although it usually occurs shortly after the acute phase of the hepatitis, it has also been reported during treatment for chronic hepatitis. 4 Therapeutic options for patients with hepatitis-associated SAA may be difficult. Although UCB transplants have been offered to adult patients with SAA, the clinical outcome has ranged from graft failure to the establishment of mixed chimerism. [5] [6] [7] Its use for adult patients with SAA associated with hepatitis C has, however, never been described. We report the successful use of a single HLA-DRB1-mismatched UCB for transplantation of an adult patient who developed SAA during treatment for hepatitis C.
A 45-year-old man was diagnosed with hepatitis C in November 2000 when his routine physical examination showed abnormal liver function tests: total protein 7.7 g/dl, albumin 4.5 g/dl, bilirubin 1.2 mg/dl, alkaline phosphatase 95 IU/l, AST 59 IU/l and ALT 124 IU/l. He had a very high viral load of 2 460 100 copies/ml, and the hepatitis C virus was subtyped as 1a. He did not have any significant past medical history or family history of bone marrow diseases. He also had no history of alcohol or intravenous drug abuse, or exposure to myelotoxic agents. The source of the viral infection was unclear but may have been related to the tattoos he had received many years previously. Liver biopsy confirmed chronic active hepatitis. He was treated with a combination of ribavirin and interferon-a (IFNa). His pretreatment complete blood counts were normal. He tolerated the combination antiviral therapy with reduction in his hepatitis C viral load. However, he developed a progressive pancytopenia that persisted despite discontinuation of the ribavirin and IFNa. By June 2002, 4 months after stopping the antiviral therapy, complete blood counts showed: hemoglobin 9.2 g/dl (reticulocyte o1%), white blood count 0.9 Â 10 9 /l (4% neutrophils, 90% lymphocytes) and platelet counts of 9 Â 10 9 /l. Bilateral bone marrow examinations on two separate occasions 2 weeks apart confirmed the diagnosis of SAA, with a bone marrow cellularity uniformly less than 5%. There was no excess of blast cells in the bone marrow. Flow cytometry and cytogenetic analyses of the bone marrow were normal. In particular, the immunophenotypic features of paroxysmal nocturnal hemaglobinuria were absent. He became symptomatic from the severe thrombocytopenia with hemorrhagic complications of mucosal bleeding, necessitating platelet transfusions twice a day, and anemia requiring blood transfusions.
Although the first-line treatment for SAA is immunosuppression in this age group, the time to response from the treatment can be as long as 6-8 weeks. During this period, patients who are heavily transfusion-dependent may require a very high level of blood product support and so are at risk of the adverse effects of blood transfusion. Furthermore, patients continue to be at risk of infection that could result in impaired patient performance status. Both these factors could influence the outcome of the treatment if the patient eventually needs a stem cell transplant. Based on these factors and due to the profound hemorrhagic complications the patient was experiencing, it was decided to treat his SAA with a hematopoietic stem cell transplant. At that time, his liver function tests had normalized and the hepatitis C viral load had fallen to below the PCR detectable limit of 10 IU/ml. An unrelated UCB transplant was offered because he did not have any siblings. He weighed 73 kg and his full HLA types were: HLA-A 01, 26; B 08, B 3801; BW-4/6 4; BW-4/6 6; DRB1 0301, 1501; DQB1 02AB; DQB1 06CYU; DRB3 01GM. His blood group was blood group O-positive. He received Busulfan 4 mg/kg/day Â 4 days and Cyclophosphamide 60 mg/kg/day Â 2 days. In vivo T-cell depletion was achieved with antithymocyte globulin 15 mg/kg/12 h Â 6 doses, starting from day À3 to day À1. He was infused with a unit of previously cryopreserved blood group A-positive unrelated UCB. The full HLA types of the infused cord blood were: A 01, A 26; B 08; B 38; BW-4/6 4; BW-4/6 6; DRB1 0301, 1401; DQB1 02AB; 05031; DRB3 01GM; DRB3 02AVK. Therefore, there was a mismatch at one of the HLA-DRB1 loci. A total of 1.77 Â 10 /kg colony-forming units were infused. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporin A starting on day À2 and methylprednisone 1 mg/kg twice a day starting on day þ 9. Grade II skin GVHD developed by day 10, but resolved spontaneously. He engrafted, achieving an absolute neutrophil count of 40.5 Â 10 9 /l on day þ 18, and became platelet transfusion independent by day þ 26. The methylprednisone was tapered starting on day þ 23 and discontinued by day þ 36. The engraftment was documented by variable number of tandem repeats (VNTR) analysis (Figure 1 ). Serological analysis of the red blood cells also showed full erythroid engraftment with the conversion of his blood group from O-positive to A-positive. He received prophylactic oral Cotrimoxazole and gancyclovir for 6 months after the transplant. His peripheral blood counts normalized by day þ 84 (hemo-globin 12.2 g/dl, white blood count 6.7 Â 10 9 /l (60% neutrophils) and platelet count 214 Â 10 9 /l). Cyclosporin A was discontinued 8 months after the transplant. He has remained well without significant GVHD 12 þ months after the transplant. The only significant post transplant complication was the development, 9 months after transplant, of shingles affecting the left facial nerve, leading to the Ramsey-Hunt syndrome. He is not requiring any immunosuppressive therapy. His liver function tests are normal and repeat hepatitis C viral studies by PCR showed a viral load still below the detectable level of 10 IU/ml.
Hepatitis-associated SAA is a condition with a very high mortality rate. Although it can be associated with hepatitis A, B and C, it occurs more commonly after a non-A, non-B or a non-C hepatitis. The aplastic anemia typically occurs a few weeks after the acute infection but has been reported to occur more than 1 year after diagnosis of the hepatitis. 8 It has also been reported to occur during treatment for hepatitis C. 4 The pathogenesis of the bone marrow aplasia remains unclear but may be related to direct viral suppression of the bone marrow progenitor cells, induction of an immune-mediated effect against the bone marrow cells, or from the medication used to control viral replication.
Although antithymocyte globulins, cyclosporin A and corticosteroids are established therapy for the treatment of aplastic anemia, their exact role in patients with viral hepatitis-associated aplastic anemia is yet to be determined in a systematic manner. Their use is rational if the bone marrow aplasia occurs as a result of immune mechanisms suppressing the hematopoietic progenitor cells. However, they have been reported to result in the exacerbation of viral replication, leading to worsening of the hepatitis. 9 Hematopoietic stem cell transplant for patients with a history of chronic viral hepatitis is associated with the risk of viral reactivation and hepatitis progression. 10, 11 Nevertheless, hepatitis-associated aplastic anemia patients have been successfully transplanted using HLA-matched sibling bone marrow. The largest series involved 19 patients with hepatitis-associated SAA and all patients were conditioned with 200 mg/kg cyclophosphamide. 12 Only one patient was positive for hepatitis C prior to the transplant. The longterm outcome was extremely favorable, with event-free survival in excess of 80%. These results suggest that hematopoietic HLA-matched sibling stem cell transplantation is a realistic option for these patients. However, the decision to transplant is more difficult if a patient does not have an HLA-matched sibling. Although unrelated adultderived hematopoietic stem cells may be used, as for the treatment of hematopoietic malignant diseases, this is normally associated with the unwanted effect of GVHD. UCB transplants that are often associated with a lower incidence of GVHD are theoretically an ideal approach. Unlike unrelated adult-derived hematopoietic stem cells, UCB can be procured easily within a short period of time. It is therefore possible to carry out the transplant before the patient is exposed to excessive allogeneic blood products with an associated increase in the risk of graft failure. Furthermore, any HLA mismatches are better tolerated in UCB transplantation, yet there have only been very few reported cases of UCB transplantation being successfully carried out for adult patients with acquired aplastic anemia. [5] [6] [7] Furthermore, none of these patients were hepatitis C positive. In these cases, the outcome was either the development of mixed chimerism or graft failure. Although mixed chimerism may result in hematologic remission of the SAA, these patients could still potentially be at risk of malignant transformation from any residual abnormal clones associated with the SAA.
The case presented here confirms that SAA can be associated with hepatitis C and can develop during the course of treatment for hepatitis C. The successful outcome in our patient suggests that UCB transplantation, even with one HLA-DRB1 mismatch, is a feasible option for adult patients over the age of 40 years. UCB transplantation for hepatitis C-associated SAA may not necessarily result in viral reactivation. This case therefore suggests that UCB transplantation could be offered to adult patients with viral hepatitis-associated SAA who need hematopoietic stem cell transplantation but do not have an HLA-matched sibling. 
